2. Signaling Pathways
  3. MAPK/ERK Pathway
  4. MAP4K
  5. MAP4K3/GLK Isoform

MAP4K3/GLK

MAP4K3, also known as germinal center kinase-like kinase (GLK), is a serine/threonine kinase that belongs to the Ste20-like kinase family and regulates T-cell activation[1]. Mechanistically, GLK phosphorylates PKCθ at Ser-538, which activates the IKK/NF-κB signaling cascade, promoting pro-inflammatory T-cell responses[1][2]. GLK further inhibits regulatory T-cell (Treg) differentiation by phosphorylating IKKβ at Ser733, leading to FoxO1 nuclear export and Foxp3 downregulation[3]. In T cells, GLK selectively stimulates IL-17A production through induction of the AhR-RORγt transcriptional complex, linking GLK signaling to autoimmune pathogenesis[4]. Compared with related MAP4K isoforms, such as HPK1/MAP4K1, GLK promotes tumorigenesis and autoimmune inflammation, highlighting its distinct functional role[1]. Overexpression of GLK in human T cells correlates with disease severity in systemic lupus erythematosus and adult-onset Still’s disease, confirming its relevance as a biomarker and pathogenic mediator[5][4]. GLK also contributes to cancer progression by phosphorylating IQGAP1, which enhances Cdc42-mediated cell migration and metastasis[1]. Pharmacological inhibition using small-molecule inhibitors such as verteporfin reduces IL-17A production and ameliorates autoimmune disease in mouse models, demonstrating translational potential[4]. These characteristics position GLK as a critical regulator of immune activation and a promising target for experimental interventions in autoimmune and cancer research[1][3][4].

MAP4K3/GLK Related Products (6):

Cat. No. Product Name Effect Purity
  • HY-111754
    DMX-5804
    		Inhibitor 99.83%
    DMX-5804 is a potent, orally active and selective MAP4K4 inhibitor, with an IC50 of 3 nM, a pIC50 of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC50, 8.18), and TNIK/MAP4K7 (pIC50, 7.96). DMX-5804 enhances cardiomyocyte survival, and reduces ischemia-reperfusion injury in mice.
  • HY-138742
    HPK1-IN-7
    		Inhibitor 99.11%
    HPK1-IN-7 is a potent, orally active HPK1 (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC50=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1.
  • HY-148061
    DB1113
    		99.86%
    DB1113 (Example 24) is a bifunctional compound targeted protein degradation of kinases. DB1113 degrades ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used for research of disease or disorder mediated by aberrant kinase activity.
  • HY-178097
    HPK1-IN-62
    		Inhibitor
    HPK1-IN-62 is a selective and orally active HPK-1 inhibitor with an IC50 of 1.22 nM. HPK1-IN-62 significantly improves GLK selectivity (> 665-fold) and LCK selectivity (> 1095-fold). HPK1-IN-62 enhances T-cell activation and demonstrated synergistic effects when combined with anti-mPD-1 therapy in the MC38 tumor model, inhibiting a tumor growth. HPK1-IN-62 can be used in the researchs of colon cancer and cancer immunotherapy.
  • HY-172107
    HPK1-IN-56
    		Inhibitor
    HPK1-IN-56 (Compound A29) is a HPK1 inhibitor (IC50: 2.70 nM). HPK1-IN-56 inhibits downstream p-SLP76 (IC50: 8.1 nM in Jurkat T cells). HPK1-IN-56 induces the production of IL-2 in human PBMCs. HPK1-IN-56 has anticancer effect, enhances T-cell killing ability and the antitumor efficacy of anti-PD-1 antibody.
  • HY-168110
    HPK1-IN-52
    		Inhibitor
    HPK1-IN-52 is a potent and orally active hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC50 value of 10.4 nM. HPK1-IN-52 exhibits anti-tumor activities.